Usynova Pharmaceuticals Ltd.

This study is testing a new oral medication called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 participants will take either the real pill or a placebo (sugar pill) for 12 weeks to see if it safely reduces skin redness, thickness, and scaling. …

This is the first study in people for a new pill called UA026, designed to treat plaque psoriasis by blocking a protein that causes inflammation. The main goal is to check the safety, side effects, and how the drug moves through the body in healthy volunteers and people with mode…